Updated: January 19, 2026
Phenazopyridine Shortage: What Providers and Prescribers Need to Know in 2026
Author
Peter Daggett

- Current Supply Status (2026)
- Why Patients Are Calling: Understanding the Access Gap
- Clinical Recommendations for Prescribers
- 1. Write Generic—Not Brand Name
- 2. Counsel Patients on the OTC Option at Time of Prescribing
- 3. Remind Patients of the 2-Day Duration Limit
- 4. Screen for Contraindications Before Prescribing
- 5. Counsel on Urinalysis Interference
- Helping Patients Find Phenazopyridine in Stock
- Key Clinical Reminders for 2026
Overview
A clinical overview of phenazopyridine availability in 2026 for providers: current supply status, patient communication strategies, and when to recommend OTC alternatives.
Is Phenazopyridine in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Phenazopyridine near you.
Phenazopyridine is a first-line adjuvant for UTI symptom management, co-prescribed alongside antibiotics to provide rapid relief from dysuria, urgency, and frequency. As of 2026, there is no FDA-declared shortage of phenazopyridine—but prescribers are regularly fielding calls from patients who can't fill the prescription at their preferred pharmacy. This guide covers what's happening with supply, how to advise patients, and practical prescribing adjustments.
Current Supply Status (2026)
The FDA Drug Shortage Database does not list phenazopyridine as of 2026. Supply of phenazopyridine is generally stable due to:
Multiple FDA-approved generic manufacturers
Mature, well-established manufacturing processes
Non-controlled substance status (no DEA scheduling)
OTC availability creating a large parallel supply channel
That said, localized pharmacy-level stockouts occur regularly, particularly at smaller independent pharmacies with limited stock. Large chain pharmacies (CVS, Walgreens, Walmart) tend to have more consistent availability of the prescription 200 mg tablet.
Check live stock now.
Why Patients Are Calling: Understanding the Access Gap
The most common patient scenario is: prescription written for phenazopyridine HCl 200 mg → pharmacy doesn't stock it or is temporarily out → patient calls your office asking what to do.
Contributing factors include:
Low inventory rationale. Because phenazopyridine is a 2-day course drug, pharmacies stock it in smaller quantities and may order infrequently.
Brand name confusion. Some patients ask for "Pyridium" by brand name; pharmacies may indicate they don't carry Pyridium (they stock generic phenazopyridine). This creates unnecessary confusion.
OTC awareness gap. Many patients don't realize the OTC version is nearly equivalent in dose and effectiveness.
Clinical Recommendations for Prescribers
1. Write Generic—Not Brand Name
Always write "phenazopyridine HCl 200 mg" rather than "Pyridium." This ensures the patient receives the most widely available and lowest-cost generic version. Pharmacies stock phenazopyridine generic extensively; few stock brand Pyridium.
2. Counsel Patients on the OTC Option at Time of Prescribing
During the visit or telehealth encounter, proactively mention: "If your pharmacy doesn't have phenazopyridine in stock, you can buy AZO Urinary Pain Relief off the shelf—it's the same drug at a slightly lower dose. Take two tablets three times daily." This one sentence can prevent a follow-up call and ensure the patient gets timely pain relief.
3. Remind Patients of the 2-Day Duration Limit
Per FDA labeling, phenazopyridine should not be used for more than 2 days when co-administered with an antibiotic for UTI treatment. After 2 days, there is no evidence of additional benefit over the antibiotic alone. Extended use risks accumulation and adverse effects including methemoglobinemia and hemolytic anemia in susceptible individuals.
Found
Rate
on average
4. Screen for Contraindications Before Prescribing
Key contraindications that should prompt use of alternative pain management:
Renal insufficiency: Phenazopyridine is renally cleared; impaired function causes drug accumulation and risk of toxicity. Contraindicated in renal failure.
G6PD deficiency: Risk of oxidative hemolysis. Avoid phenazopyridine in patients with known G6PD deficiency.
Hepatic impairment: Use with caution; avoid in severe hepatic disease.
Elderly patients: Monitor carefully due to age-related decline in renal function. Yellowing of skin or sclera should prompt immediate discontinuation.
5. Counsel on Urinalysis Interference
Phenazopyridine interferes with urinalysis dipstick tests and spectrophotometric assays. If a urine culture or UA is planned, it should be collected before starting phenazopyridine, or phenazopyridine should be discontinued for an appropriate period before urine testing. Failure to account for this can produce false results for urine glucose, ketones, and bilirubin.
Helping Patients Find Phenazopyridine in Stock
When patients can't find phenazopyridine at their pharmacy, you can refer them to medfinder.com/providers. medfinder calls pharmacies near the patient to identify which ones have the medication in stock, then texts the patient the results. This reduces follow-up calls to your office and ensures the patient gets timely access to their medication.
Key Clinical Reminders for 2026
Write "phenazopyridine HCl 200 mg"—not "Pyridium"
Counsel patients that OTC AZO is a same-drug alternative if the Rx form is unavailable
Limit use to 2 days with antibiotic co-prescription
Screen for renal insufficiency and G6PD deficiency before prescribing
Obtain urine culture before initiating phenazopyridine to avoid interference
Warn about orange urine discoloration and contact lens staining
For a complete provider guide on helping patients access phenazopyridine, see: How to Help Your Patients Find Phenazopyridine in Stock.
Frequently Asked Questions
No. As of 2026, phenazopyridine is not listed on the FDA Drug Shortage Database. Supply is generally stable due to multiple generic manufacturers and OTC availability. Local pharmacy stockouts occur but are not indicative of a nationwide supply problem.
Advise patients to purchase OTC AZO Urinary Pain Relief or Uristat at any pharmacy or grocery store—no prescription needed. Two OTC tablets (97.5 mg each) provide a dose comparable to the prescription 200 mg tablet. They can also use medfinder.com to find which pharmacies near them have the prescription form in stock.
Per FDA labeling, phenazopyridine should not be used for more than 2 days when co-administered with an antibiotic for UTI treatment. There is no evidence of additional benefit beyond 2 days. Extended use increases the risk of adverse effects including methemoglobinemia and renal toxicity.
Phenazopyridine is contraindicated in patients with renal insufficiency (it accumulates dangerously when kidneys cannot clear it), G6PD deficiency (risk of hemolytic anemia), and known hypersensitivity to the drug. Use with caution in elderly patients and those with hepatic impairment. Monitor for yellowing of skin or eyes, which indicates drug accumulation.
Yes. Phenazopyridine's azo dye properties interfere with dipstick urinalysis tests and spectrophotometric assays, producing false results for glucose, ketones, bilirubin, and other markers. Urine culture and UA should ideally be obtained before initiating phenazopyridine. If a urine test is needed while the patient is on phenazopyridine, note this on the order to alert the lab.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Phenazopyridine also looked for:
More about Phenazopyridine
38,224 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





